{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:04:12Z","timestamp":1783951452334,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40263-018-0551-3","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T02:30:27Z","timestamp":1532658627000},"page":"827-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism"],"prefix":"10.1007","volume":"32","author":[{"given":"Nikolaos","family":"Giagkou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-9925","authenticated-orcid":false,"given":"Maria","family":"Stamelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"551_CR1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord."},{"key":"551_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1750-3639.2012.00611.x","volume":"23","author":"J Horvath","year":"2013","unstructured":"Horvath J, Burkhard PR, Bouras C, K\u00f6vari E. Etiologies of Parkinsonism in a century-long autopsy-based cohort. Brain Pathol. 2013;23:28\u201333.","journal-title":"Brain Pathol."},{"key":"551_CR3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tr\u00f6ster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503.","journal-title":"Neurology."},{"key":"551_CR4","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, D\u00fcrr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670\u20136.","journal-title":"Neurology."},{"key":"551_CR5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, M\u00fcller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, Boxer AL, Rajput A, Pantelyat A, Antonini A, Lang AE, Giese A, Mollenhauer B, Colosimo C, Kurz C, Nilsson C, Troakes C, Irwin DJ, Dickson DW, Gelpi E, Krismer F, Schellenberg GD, Respondek G, Rabinovici G, Wenning GK, H\u00f6glinger GU, Morris HR, Litvan I, Rowe JB, Kassubek J, Corvol JC, Whitwell JL, Levin J, van Swieten J, Bhatia KP, Josephs KA, Seppi K, Golbe LI, Stamelou M, Grossman M, Nestor P, Dodel R, Lorenzl S, van Eimeren T, Arzberger T, M\u00fcller U, Meissner WG, Poewe W, Oertel WH, Compta Y, Bordelon Y. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853\u201364.","journal-title":"Mov Disord."},{"key":"551_CR6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1212\/WNL.0000000000001807","volume":"85","author":"S Koga","year":"2015","unstructured":"Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology. 2015;85:404\u201312.","journal-title":"Neurology."},{"key":"551_CR7","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","volume":"29","author":"G Respondek","year":"2014","unstructured":"Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, van Swieten JC, Troakes C, Al Sarraj S, Gelpi E, Gaig C, Tolosa E, Oertel WH, Giese A, Roeber S, Arzberger T, Wagenpfeil S, H\u00f6glinger GU. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29:1758\u201366.","journal-title":"Mov Disord."},{"key":"551_CR8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372:249\u201363.","journal-title":"N Engl J Med."},{"key":"551_CR9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL, Yu J-T, Golbe LI, Litvan I, Lang AE, H\u00f6glinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16:552\u201363.","journal-title":"Lancet Neurol."},{"key":"551_CR10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12031-011-9624-1","volume":"45","author":"BF Boeve","year":"2011","unstructured":"Boeve BF. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: Implications for further study. J Mol Neurosci. 2011;45:350\u20133.","journal-title":"J Mol Neurosci."},{"key":"551_CR11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jnnp-2013-307035","volume":"85","author":"SK Alexander","year":"2014","unstructured":"Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 2014;85:923\u20137.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"551_CR12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mds.27034","volume":"32","author":"G Respondek","year":"2017","unstructured":"Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, M\u00fcller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, H\u00f6glinger GU. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. 2017;32:995\u20131005.","journal-title":"Mov Disord."},{"key":"551_CR13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp.67.5.620","volume":"67","author":"GK Wenning","year":"1999","unstructured":"Wenning GK, Scherfler C, Granata R, B\u00f6sch S, Verny M, Chaudhuri KR, Jellinger K, Poewe W, Litvan I. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1999;67:620\u20133.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"551_CR14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.parkreldis.2017.02.027","volume":"38","author":"WRW Martin","year":"2017","unstructured":"Martin WRW, Hartlein J, Racette BA, Cairns N, Perlmutter JS. Pathologic correlates of supranuclear gaze palsy with parkinsonism. Parkinsonism Relat Disord. 2017;38:68\u201371.","journal-title":"Parkinsonism Relat Disord."},{"key":"551_CR15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2990.2007.00907.x","volume":"33","author":"JQ Trojanowski","year":"2007","unstructured":"Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol. 2007;33:615\u201320.","journal-title":"Neuropathol Appl Neurobiol."},{"key":"551_CR16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/brain\/aww230","volume":"140","author":"M Goedert","year":"2017","unstructured":"Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and \u03b1-synuclein in neurodegeneration. Brain. 2017;140:266\u201378.","journal-title":"Brain."},{"key":"551_CR17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/brain\/117.2.235","volume":"117","author":"MI Papp","year":"1994","unstructured":"Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1994;117:235\u201343.","journal-title":"Brain."},{"issue":"2","key":"551_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/jnnp-2017-315813","volume":"89","author":"S Koga","year":"2018","unstructured":"Koga S, Dickson DW. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry. 2018;89(2):175\u201384.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"551_CR19","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/brain\/awh303","volume":"127","author":"T Ozawa","year":"2004","unstructured":"Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, Healy DG, Wood NW, Lees AJ, Holton JL, Revesz T. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004;127:2657\u201371.","journal-title":"Brain."},{"key":"551_CR20","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1093\/brain\/awv114","volume":"138","author":"MD Cykowski","year":"2015","unstructured":"Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, Schmeichel AM, Parisi JE. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138:2293\u2013309.","journal-title":"Brain."},{"key":"551_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nan.12208","volume":"41","author":"GG Kovacs","year":"2015","unstructured":"Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41:3\u201323.","journal-title":"Neuropathol Appl Neurobiol."},{"key":"551_CR22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","volume":"23","author":"DW Dickson","year":"2010","unstructured":"Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394\u2013400.","journal-title":"Curr Opin Neurol."},{"key":"551_CR23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","volume":"61","author":"DW Dickson","year":"2002","unstructured":"Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61:935\u201346.","journal-title":"J Neuropathol Exp Neurol."},{"key":"551_CR24","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.parkreldis.2015.09.023","volume":"22","author":"L Marsili","year":"2016","unstructured":"Marsili L, Suppa A, Berardelli A, Colosimo C. Therapeutic interventions in parkinsonism: corticobasal degeneration. Park Relat Disord. 2016;22:S96\u2013100.","journal-title":"Park Relat Disord."},{"key":"551_CR25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2016.01.005","volume":"24","author":"WG Meissner","year":"2016","unstructured":"Meissner WG, Laurencin C, Tranchant C, Witjas T, Viallet F, Guehl D, Damier P, Houeto JL, Tison F, Eusebio A, Vital A, Streichenberger N, Lannes B, Maues de Paula A, Thobois S. Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature. Park Relat Disord. 2016;24:69\u201375.","journal-title":"Park Relat Disord."},{"key":"551_CR26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40263-016-0347-2","volume":"30","author":"M Stamelou","year":"2016","unstructured":"Stamelou M, H\u00f6glinger G. A review of treatment options for progressive supranuclear palsy. CNS Drugs. 2016;30:629\u201336.","journal-title":"CNS Drugs."},{"key":"551_CR27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40263-017-0478-0","volume":"31","author":"S M\u00fcller-Rebstein","year":"2017","unstructured":"M\u00fcller-Rebstein S, Trenkwalder C, Ebentheuer J, Oertel WH, Culmsee C, H\u00f6glinger GU. Drug safety analysis in a real-life cohort of Parkinson\u2019s disease patients with polypharmacy. CNS Drugs. 2017;31:1093\u2013102.","journal-title":"CNS Drugs."},{"key":"551_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870120203","volume":"12","author":"GK Wenning","year":"1997","unstructured":"Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12:133\u201347.","journal-title":"Mov Disord."},{"key":"551_CR29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11940-016-0422-5","volume":"18","author":"R Lamb","year":"2016","unstructured":"Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18:42.","journal-title":"Curr Treat Options Neurol."},{"key":"551_CR30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/nmt-2016-0027","volume":"6","author":"T Rittman","year":"2016","unstructured":"Rittman T, Coyle-Gilchrist IT, Rowe JB. Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag. 2016;6:499\u2013508.","journal-title":"Neurodegener Dis Manag."},{"key":"551_CR31","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/j.1572-0241.2007.01255.x","volume":"102","author":"SC Reddymasu","year":"2007","unstructured":"Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036\u201345.","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"551_CR32","first-page":"III\/24","volume":"249","author":"WH Jost","year":"2002","unstructured":"Jost WH, Br\u00fcck C. Drug interactions in the treatment of Parkinson\u2019s disease. J Neurol. 2002;249(Suppl 1):III\/24\u20139.","journal-title":"J Neurol."},{"key":"551_CR33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.autneu.2017.10.006","volume":"211","author":"G Rohrer","year":"2018","unstructured":"Rohrer G, H\u00f6glinger GU, Levin J. Symptomatic therapy of multiple system atrophy. Auton Neurosci. 2018;211:26\u201330.","journal-title":"Auton Neurosci."},{"key":"551_CR34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/bs.irn.2017.06.001","volume":"134","author":"KP Bhatia","year":"2017","unstructured":"Bhatia KP, Stamelou M. Nonmotor features in atypical parkinsonism. Int Rev Neurobiol. 2017;134:1285\u2013301.","journal-title":"Int Rev Neurobiol"},{"key":"551_CR35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.57.3.467","volume":"57","author":"I Litvan","year":"2001","unstructured":"Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57:467\u201373.","journal-title":"Neurology."},{"key":"551_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1600-0404.2001.103002123.x","volume":"103","author":"G Fabbrini","year":"2001","unstructured":"Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, Meco G. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103:123\u20135.","journal-title":"Acta Neurol Scand."},{"key":"551_CR37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11940-013-0282-1","volume":"16","author":"MJ Armstrong","year":"2014","unstructured":"Armstrong MJ. Diagnosis and treatment of corticobasal degeneration topical collection on movement disorders. Curr Treat Options Neurol. 2014;16:282.","journal-title":"Curr Treat Options Neurol."},{"key":"551_CR38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.26918","volume":"32","author":"A Videnovic","year":"2017","unstructured":"Videnovic A. Management of sleep disorders in Parkinson\u2019s disease and multiple system atrophy. Mov Disord. 2017;32:659\u201368.","journal-title":"Mov Disord."},{"key":"551_CR39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrurol.2016.254","volume":"14","author":"T Ogawa","year":"2017","unstructured":"Ogawa T, Sakakibara R, Kuno S, Ishizuka O, Kitta T, Yoshimura N. Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol. 2017;14:79\u201389.","journal-title":"Nat Rev Urol."},{"key":"551_CR40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11940-016-0427-0","volume":"18","author":"A Batla","year":"1940","unstructured":"Batla A, Tayim N, Pakzad M, Panicker JN. Treatment options for urogenital dysfunction in Parkinson\u2019s disease. Curr Treat Options Neurol. 1940;18:45.","journal-title":"Curr Treat Options Neurol."},{"issue":"1","key":"551_CR41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10286-017-0480-0","volume":"28","author":"R Sakakibara","year":"2018","unstructured":"Sakakibara R, Tateno F, Yamamoto T, Uchiyama T, Yamanishi T. Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management. Clin Auton Res. 2018;28(1):83\u2013101.","journal-title":"Clin Auton Res."},{"key":"551_CR42","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","volume":"182","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson\u2019s disease and multiple system atrophy. J Urol. 2009;182:1453\u20137.","journal-title":"J Urol."},{"key":"551_CR43","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00415-016-8375-x","volume":"264","author":"CH Gibbons","year":"2017","unstructured":"Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264:1567\u201382.","journal-title":"J Neurol."},{"key":"551_CR44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11940-016-0435-0","volume":"18","author":"S Maa\u00df","year":"2016","unstructured":"Maa\u00df S, Levin J, H\u00f6glinger G. Current treatment of multiple system atrophy. Curr Treat Options Neurol. 2016;18:51.","journal-title":"Curr Treat Options Neurol."},{"key":"551_CR45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CRD.0000000000000151","volume":"25","author":"N Ferguson-Myrthil","year":"2017","unstructured":"Ferguson-Myrthil N. Droxidopa for symptomatic neurogenic hypotension. Cardiol Rev. 2017;25:241\u20136.","journal-title":"Cardiol Rev."},{"key":"551_CR46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","volume":"72","author":"PH Lee","year":"2012","unstructured":"Lee PH, Lee JE, Kim H-S, Song SK, Lee HS, Nam HS, Cheong J-W, Jeong Y, Park H-J, Kim DJ, Nam CM, Lee JD, Kim HO, Sohn YH. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012;72:32\u201340.","journal-title":"Ann Neurol."},{"key":"551_CR47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-12-131","volume":"12","author":"P Novak","year":"2012","unstructured":"Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol. 2012;12:131.","journal-title":"BMC Neurol."},{"key":"551_CR48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533\u201340.","journal-title":"Lancet."},{"key":"551_CR49","first-page":"pyu027","volume":"18","author":"JAM Smith","year":"2014","unstructured":"Smith JAM, Bourdet DL, Patil DL, Daniels OT, Ding Y-S, Gallezot J-D, Henry S, Kim KHS, Kshirsagar S, Martin WJ, Obedencio GP, Stangeland E, Tsuruda PR, Williams W, Carson RE, Patil ST. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014;18:pyu027.","journal-title":"Int J Neuropsychopharmacol."},{"key":"551_CR50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2337\/dc13-1672","volume":"37","author":"V Novak","year":"2014","unstructured":"Novak V, Milberg W, Hao Y, Munshi M, Novak P, Galica A, Manor B, Roberson P, Craft S, Abduljalil A. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care. 2014;37:751\u20139.","journal-title":"Diabetes Care."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0551-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T14:38:21Z","timestamp":1604068701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0551-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0551-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"27 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nikolaos Giagkou and Maria Stamelou have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}